You are here
NOVOBIOTIC PHARMACEUTICALS, LLC
UEI: GUV4CZLZE5Z2
# of Employees: 12
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Antifungal discovery from previously uncultivated bacteria
Amount: $299,997.00ABSTRACT Candida auris is a multidrug-resistant yeast that can cause invasive infection and death. It spreads easily between hospitalized patients and nursing home residents. C. auris is especially ha ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Teixobactin Development for Tuberculosis
Amount: $1,996,273.00ABSTRACT The goal of this proposal is to investigate the potential for teixobactin (TXB) to treat drug-resistant tuberculosis (TB). TB is a major global health issue and second largest killer by an in ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Antibiotic discovery from a new genus of uncultured bacteria.
Amount: $596,026.00Abstract: The current antimicrobial resistance crisis is caused by the rise and spread of drug resistant pathogens. According to the WHO, drug-resistant E. coli, K. pneumoniae, P. aeruginosa, A. bauma ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Teixobactin Development for Anthrax
Amount: $2,989,150.00ABSTRACTThe goal of this project is to continue developing teixobactin (TXB) as an antibiotic to combat weaponized anthrax. This work will be done in parallel to an ongoing preclinical development pro ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Preclinical development of Novo29, a new antibiotic
Amount: $2,964,879.00The goal of this program is to continue developing our novel antimicrobial, Novo29, into a therapeutic for treating a wide range of infections caused by Gram-positive pathogens including Staphylococcu ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Preclinical development of Novo29, a new antibiotic
Amount: $231,409.00Abstract The overall goal of this project is to conduct preclinical studies on Novoour newly discovered bactericidal compoundAs drug resistance continues to spreadnew classes of antibiotics are needed ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Preclinical development of teixobactin, a new antibiotic
Amount: $2,995,488.00The long-term goal of this program is to develop our novel antimicrobial, teixobactin, into a therapeutic for treating a wide range of infections caused by Gram-positive pathogens including Staphyloco ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
Novel Antibiotics from Marine Invertebrate Microbes
Amount: $586,229.00ABSTRACTThe rise of multi drug resistant pathogensparticularly ESKAPE pathogensis a major public health concernOne effective countermeasure against such pathogens is novel antibioticsbut the rate of a ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Exploratory Chemistry on a new antibiotic
Amount: $1,484,593.00This project studies the structure activity relationship SAR of the newly discovered antibiotic teixobactin with the goal of delivering a candidate that has development advantages over the parent c ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Specific anti-TB compounds from uncultured bacteria
Amount: $219,069.00DESCRIPTION provided by applicant The slow pace of antibiotic discovery is being outmatched by rapid acquisition of resistance by our pathogens The need is especially acute in the case of Mycobact ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health
